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Two  hundred  healthy  subjects  were  enrolled  in a randomised,  partially  double-blinded,  single-centre,
parallel  design  thorough  QT  study  to  demonstrate  that dalbavancin  had  no  clinical  effect  on  the  12-lead
ECG  QTc.  Fifty  patients  in each  group  received  either  dalbavancin  1000  mg  intravenous  (i.v.), dalbavancin
1500  mg  i.v.  or placebo  i.v., each  infused  over  30  min,  or  400  mg  oral  moxiﬂoxacin.  Ten replicate  12-lead
ECGs  were  extracted  at pre-deﬁned  time  points  before  and  up to 24  h post  dosing  and  at  corresponding
time  points  during  baseline.  Dalbavancin  did  not  have  an  effect  on  the  QTcF  interval,  and  an  effect  exceed-
ing  10  ms  could  be excluded  at all time  points  after  a single  i.v. dose  of  1000  mg and  1500  mg.  The largest
placebo-corrected  change-from-baseline  QTcF  (QTcF)  was  1.5  ms  in  the  1000  mg  dalbavancin  group
at 6 h  and  0.2  ms in the  1500  mg  group  at 24  h. A small  concentration-dependent  effect  of  dalbavancin
on  QTcF  was  identiﬁed  with  an  estimated  negative  population  slope  of −0.0051  ms  per  g/mL.  Assay
sensitivity  was  demonstrated  by the  effect  of  400  mg  moxiﬂoxacin,  which  peaked  at  2  h at  QTcF  of
12.9  ms,  with  the  lower  bound  of the  90%  CI of  the effect  exceeding  5  ms  at all  three  pre-deﬁned  time
points.  Dalbavancin  did  not  exert  a relevant  effect  on  heart  rate  or  PR  or  QRS  intervals.  Dalbavancin  in
i.v. doses  up  to 1500  mg  did  not  prolong  the  QTc  interval  and  had  no  effect  on  heart  rate  or  PR  and  QRS
intervals.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  on  behalf  of  International  Society  of Chemotherapy.
This  is  an  open  access  article  under  the CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Dalbavancin is a lipoglycopeptide antibiotic that is obtained
y chemical modiﬁcation of a natural glycopeptide. Glycopeptide
ntibiotics inhibit the biosynthesis of bacterial cell wall peptido-
lycan. By binding to the d-alanyl-d-alanine terminus of the stem
entapeptides in nascent peptidoglycan, the formation of cross-
inks that stabilise the cell wall structure is blocked. In vitro and
n vivo non-clinical microbiology and pharmacology data provide
vidence for the potential therapeutic usefulness of dalbavancin in
he treatment of clinical infections caused by Gram-positive bacte-
ia. The safety and efﬁcacy of intravenous (i.v.) dalbavancin for
he treatment of acute bacterial skin and skin-structure infections
∗ Corresponding author. Tel.: +1 203 871 4602.
E-mail addresses: michael.w.dunne@comcast.net, mdunne@duratatx.com
M.W.  Dunne).
ttp://dx.doi.org/10.1016/j.ijantimicag.2014.12.021
924-8579/© 2015 The Authors. Published by Elsevier B.V. on behalf of International Soci
http://creativecommons.org/licenses/by-nc-nd/4.0/).(ABSSSIs), in particular those caused by staphylococci and strepto-
cocci, have been studied in two  phase 3 clinical trials [1].
In safety pharmacology studies, dalbavancin did not affect the
cardiac hERG current or the action potential duration in in vitro
assays and did not prolong the QTc interval in conscious or
anaesthetised dogs at plasma concentrations exceeding clinical,
therapeutic peak plasma levels (Cmax). Several studies in conscious
and anaesthetised dogs identiﬁed a slight but consistent tendency
for blood pressure to decrease during or soon after dalbavancin
infusion, with a slight increase in heart rate, which was  inter-
preted as compensatory to the reduction in blood pressure. These
haemodynamic effects were accompanied by clinical signs of facial
or paw erythema and swelling and are therefore considered possi-
bly related to histamine release in this species.The pharmacokinetic (PK) proﬁle of dalbavancin in humans is
characterised by very low interpatient variability and a terminal
half-life of ca. 14 days. These characteristics support the two-dose
regimen approved by the US Food and Drug Administration (FDA)
ety of Chemotherapy. This is an open access article under the CC BY-NC-ND license
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or treatment of ABSSSI of 1000 mg  i.v. over 30 min  followed 1 week
ater by 500 mg.
As part of the overall safety assessment of dalbavancin, this
tudy was conducted to evaluate whether dalbavancin at therapeu-
ic and supratherapeutic plasma levels has any clinically relevant
ffects on electrocardiogram (ECG) parameters, as recommended
y regulatory guidance [2,3]. A supratherapeutic dose of 1500 mg
as chosen as it was expected to result in plasma levels signiﬁ-
antly above those seen in patients on the ﬁrst day of dosing.
. Methods
This study was randomised and partially double-blinded with
he primary objective of demonstrating that therapeutic and
upratherapeutic plasma exposures to dalbavancin after a single
.v. infusion of 1000 mg  and 1500 mg  does not have an effect on
he QTc interval exceeding 10 ms.  In total, 200 healthy adult sub-
ects (with ≥30% females) were to be enrolled in the study. Subjects
ho met  all eligibility criteria and who agreed to participate in the
tudy were randomly assigned to one of the following treatment
roups:
A (therapeutic dalbavancin dose): 325 mL  of 1000 mg  dalbavancin
solution administered intravenously over 30 min;
B (supratherapeutic dalbavancin dose): 325 mL  of 1500 mg  dalba-
vancin solution administered intravenously over 30 min;
C (placebo): 325 mL  of dalbavancin placebo solution (5% Dextrose
for Injection, USP, 250 mL  with Sterile Water for Injection, USP,
75 mL)  administered intravenously over 30 min; and
D (oral moxiﬂoxacin):  325 mL  of dalbavancin placebo solution (5%
Dextrose for Injection, USP, 250 mL  with Sterile Water for Injec-
tion, USP, 75 mL)  administered intravenously over 30 min  and one
tablet of 400 mg  moxiﬂoxacin hydrochloride (AVELOX®; Bayer
HealthCare Pharmaceuticals Inc., Wayne, NJ) administered orally
at the start of the infusion with ca. 240 mL  (8 ﬂuid ounces) of
room temperature water.
Subjects were screened within 28 days (between Day-30 and
ay-3) prior to the study and were admitted to the clinical unit on
ay-2 and were conﬁned until Day 2. During and across all study
reatment groups, meals, ﬂuid intake and environmental factors
emained as constant as possible.
.1. Electrocardiogram assessment
Continuous 12-lead ECGs were recorded on Day-1 and Day 1
nd until 24 h post dose on Day 2 using an M12R Holter recorder
Global Instrumentation, Manlius, NY). The continuous 12-lead dig-
tal ECG data were stored onto SD memory cards and were not
vailable for review until the cards were received by the central
CG laboratory (iCardiac Technologies, Rochester, NY) and ana-
ysed. ECGs were extracted at time points that were selected to
over the anticipated peak plasma level of dalbavancin and a sufﬁ-
ient number of time points thereafter to characterise any potential
ffect on the QT/QTc interval post dosing: 10 min  prior to dosing
0 h) and 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h after the start of infusion
nd at corresponding time points at baseline (Day-1). ECGs were
xtracted from the continuous recording using proprietary soft-
are (TQT Plus; iCardiac Technologies) in up to 10 replicates at each
ime point. Non-overlapping 10-s ECG recordings were extracted
rom the 5-min time window preceding each time point. QT and
R interval were measured in all recorded beats with the High
recision QT technique, whereby measurements on beats deemed
high conﬁdence’ were performed using the COMPAS (University
f Rochester, Rochester, NY) software [4]. All low conﬁdence beatstimicrobial Agents 45 (2015) 393–398
were reviewed manually and were either rejected using pass–fail
criteria or accepted without manual adjustment of ﬁducial points.
The ﬁnal QC assessment was performed by a cardiologist. Cate-
gorical T-wave morphology analysis and measurement of PR and
QRS intervals were performed manually in three of the ten ECG
replicates with the highest quality at each time point, based on
prospective deﬁned criteria [5].
2.2. Pharmacokinetic determination
Blood samples were collected before dosing and at 0.5, 1, 2,
3, 4, 6, 8, 10, 12 and 24 h after the start of infusion. Only plasma
samples from the dalbavancin treatment groups were analysed
using a validated liquid chromatography–tandem mass spectrom-
etry (LC–MS/MS) method.
2.3. Statistical analysis
The primary analysis for each dose of dalbavancin was  based
on the QT/QTc analysis set. An analysis of covariance model
with the change from time-matched baseline as dependent vari-
able, treatment (supratherapeutic dose, therapeutic dose, placebo)
and sex as factor, and time-matched baseline as covariate was
ﬁtted. A two-sided 90% conﬁdence interval (CI) was calculated
for the contrasts ‘therapeutic dose of dalbavancin–placebo’ and
‘supratherapeutic dose of dalbavancin–placebo’. Such a model was
ﬁtted for each time point on Day 1. Hypotheses were based upon
the intersection–union test as speciﬁed below. To evaluate the drug
effect, the statistical hypotheses can be stated as follows:
HO: ∪{drug(i) − placebo(i)} ≥ x, i = 1, 2, . . .,  10 and
HA: ∩{drug(i) − placebo(i)} < x, i = 1, 2, . . .,  10.
where drug(i) and placebo(i) are the mean change from baseline
of QTcF for the drug and placebo at each time point, respectively.
Since the intersection–union test can be applied here, no multiple
endpoint adjustment was  needed [6]. If the upper limit of the two-
sided 90% CI for the supratherapeutic dose of dalbavancin versus
placebo falls below 10 ms  for all time points, it was to be concluded
that the supratherapeutic dose does not prolong the QTc interval to
a clinically signiﬁcant degree. The procedure was repeated for the
therapeutic dose of dalbavancin. The analysis to show assay sensi-
tivity was  based on QTcF in the moxiﬂoxacin treatment group.
For each time point, an analysis of covariance model was ﬁtted
with treatment (moxiﬂoxacin, placebo) and sex as factor and time-
matched baseline as covariate. For the time points 2, 3 and 4 h
after dosing, a two-sided 90% CI was  calculated for the contrast
‘moxiﬂoxacin–placebo’. Since the alternative hypothesis is that at
least one of the time points is ≥5 ms,  a multiplicity adjustment was
necessary [7]. Therefore, the CIs were calculated using an adjusted
 ˛ level based on the Hochberg procedure [8]. Assay sensitivity
was established if there was  at least one time point at which the
lower conﬁdence bound of the mean difference of moxiﬂoxacin and
placebo was  >5 ms.
For heart rate and for PR and QRS intervals as well as change from
baseline for QTcF, similar ﬁgures were generated based on descrip-
tive statistics. Categorical outliers and T-wave morphology were
summarised by treatment and visit in frequency tables with counts
and percentages for both number of subjects and number of time
points. For categorical outliers, the number (%) of subjects as well as
time points that had increases in QTc from baseline of >30 ms  and
>60 ms  and absolute QTc values >450, >480 and >500 ms  were pre-
sented by treatment group, respectively. For T-wave morphology,
the analysis was  focused on change from baseline (treatment-
emergent changes).
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Fig. 2. Change from time-matched baseline heart rate (HR) (mean and 90% conﬁ-M.W. Dunne et al. / International Journa
The relationship between placebo-corrected QTcF (QTcF)
nd dalbavancin concentrations was investigated by a linear
ixed-effects modelling approach [9,10]:
QTcFij = Intercepti − slopei × Concij + εij
here QTcFij was the time-matched, placebo-corrected
hange-from-baseline QTcF for subject i at time j with dalbavancin
oncentration Concij. The residual ij was assumed to be identical,
ndependent, normally distributed (iidN) with mean 0 and variance
2.
Three linear models were considered: (a) with an intercept; (b)
ith mean intercept ﬁxed to 0 (with variability); and (c) with no
ntercept, i.e. a linear model with only slope. Time-matched con-
entration was included in the model as a variable and subjects as
 random effect for both intercept and slope, whenever applica-
le. A plot of standardised residuals versus ﬁtted values was used
o examine departure from model assumptions. The normal Q–Q
lots of the random effects and the within-subject errors were used
o investigate the normality of the random effects and the within-
ubject errors, respectively. A ﬁnal assessment of the adequacy of
he linear mixed-effects model was provided by a goodness-of-ﬁt
lot (i.e. the observed concentration quantile—QTcF plot) as
roposed by the FDA’s Interdisciplinary Review Team [11]. Such a
lot was used to check the assumption of linearity between dal-
avancin concentrations and QTcF and how well the predicted
QTcF matched the observed data in the regions of interest. The
ean QTcF at the observed geometric mean Cmax was calcu-
ated. Since Cmax is usually log-normally distributed, the geometric
ean is more appropriate to use than the arithmetic mean [11].
. Results
In total, 200 healthy subjects (119 female and 81 male) were
nrolled and 50 were assigned to each of the four treatments. The
nalysed population consisted of 50 subjects each in the dalba-
ancin 1000 mg  and moxiﬂoxacin treatment groups, 49 subjects
n the placebo group and 48 subjects in the dalbavancin 1500 mg
roup; 3 patients did not have ECG data available post base-
ine. The mean ± standard deviation (S.D.) age of the subjects was
8.8 ± 10.0 years (range, 18–55 years) and the mean ± S.D. weight
as 73.1 ± 11.6 kg..1. Pharmacokinetics
Plasma concentrations after infusion of 1000 mg  and 1500 mg
albavancin are shown in Fig. 1. After receiving a 1000 mg
Fig. 1. Mean plasma concentration (0–24 h) for ddence interval) across treatment groups. The observed diurnal pattern was similar
in  all groups and dalbavancin did not have an apparent effect on heart rate.
dalbavancin i.v. infusion, the mean exposure after 24 h [24-
h area under the concentration–time curve (AUC0–24 h)] was
3184.82 g h/mL with a mean Cmax of 287.3 g/mL occurring at a
median of 0.62 h. After receiving a 1500 mg  dalbavancin i.v. infu-
sion, the mean AUC0–24 h was  4836.64 g h/mL with a mean Cmax
of 422.6 g/mL occurring at a median of 0.62 h.
3.2. Electrocardiographic effects
At baseline (Day-1), ECG parameters were well balanced across
treatment groups, with mean heart rate between 63 bpm and
67 bpm, mean QTcF between 405.3 ms  and 407.9 ms,  mean PR
between 135.6 ms  and 141.2 ms,  and mean QRS between 103.7 ms
and 105.9 ms.
There was an initial small increase of heart rate immediately
before and after the infusion compared with the baseline day in
all treatment groups (Fig. 2). This effect peaked at 1 h (30 min
after the end of the infusion), with a change-from-baseline HR
(HR) of 3–5 bpm in all treatment groups. Heart rate changes at all
other time points were small and within 4 bpm for all groups. The
mean placebo-corrected change-from-baseline heart rate (HR)
was small for all active treatments. The largest mean HR was
2.0 bpm (90% CI 0.2 to 3.9) at 3 h in the dalbavancin 1000 mg  group,
2.4 bpm (90% CI−0.2 to 4.9) at 8 h in the dalbavancin 1500 mg  group
and 3.4 bpm (90% CI 1.1 to 5.7) at 3 h in the moxiﬂoxacin group.
albavancin 1000 mg () and 1500 mg ().
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Table 1
Placebo-corrected change from time-matched baseline QTcF (QTcF, in ms)a.
Time (h) Mean SE 90% CI Mean SE 90% CI
Lower Upper Lower Upper
1000 mg  Dalbavancin 1500 mg Dalbavancin
0 −1.4 1.6 −4.1 1.2 −4.0 1.6 −6.6 −1.3
0.5  −1.5 1.6 −4.2 1.2 −1.5 1.7 −4.3 1.2
1  0.3 1.6 −2.3 2.9 −1.3 1.6 −4.0 1.3
2  −1.1 1.4 −3.4 1.1 −1.5 1.4 −3.8 0.7
3  −1.0 1.8 −3.9 1.9 −4.1 1.8 −7.1 −1.2
4  −0.4 1.5 −2.9 2.0 −1.7 1.5 −4.2 0.8
6  1.5 1.3 −0.6 3.6 −0.4 1.3 −2.5 1.8
8  −2.3 1.3 −4.5 −0.1 −3.3 1.3 −5.5 −1.0
10  −2.1 1.4 −4.4 0.3 −1.6 1.5 −4.0 0.8
12  −1.2 1.1 −3.1 0.7 −2.0 1.1 −3.9 −0.2
24  −0.1 1.1 −1.9 1.6 0.2 1.1 −1.7 2.0
Moxiﬂoxacin
0 −1.7 1.4 −3.9 0.6
0.5  1.3 1.7 −1.5 4.1
1  3.4 1.8 0.4 6.4
2  12.9 1.4 10.5 15.2
3  9.2 1.2 7.1 11.3
4  10.9 1.4 8.6 13.3
6  7.7 1.4 5.3 10.0
8  6.3 1.3 4.1 8.6
10  8.7 1.5 6.3 11.2
12  8.1 1.1 6.3 9.8
24  5.7 1.0 4.0 7.4
S
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dE, standard error; CI, conﬁdence interval.
a Results from the statistical modelling.
In all treatment groups, mean QTcF was somewhat shorter
t the pre-dose, 0.5-h and 1-h time points compared with the
ime-matched baseline, with no clear differences across treatments
Fig. 3). In the moxiﬂoxacin group, a clear increase of the change-
rom-baseline QTcF (QTcF) was observed from 2 to 12 h post
osing, and this effect peaked at 4 h with a mean QTcF 10.0 ms
90% CI 8.0 to 11.9). Dalbavancin did not have an effect on the QTcF
nterval, with the QTcF pattern across time points being simi-
ar between both doses of dalbavancin and placebo. The largest
ean placebo-corrected QTcF (QTcF) was 1.5 ms  (90% CI–0.6
o 3.6) at 6 h after dosing of dalbavancin 1000 mg  and 0.2 ms  (90%
I–1.7 to 2.0) at 24 h after dosing of dalbavancin 1500 mg;  QTcF
as negative at all other time points after the 1500 mg  dose, withhe largest shortening observed at 3 h (−4.1 ms;  90% CI−7.1 to
1.2) (Table 1). The study’s ‘assay sensitivity’ was conﬁrmed by the
lacebo-corrected QTcF (QTcF) response after a single-dose
f 400 mg  moxiﬂoxacin. The mean peak QTcF effect reached
-15.0
-10.0
-5.0
0.0
5.0
10.0
15.0
-2 262422201816141210 86420
Time  (hour)
A (1000 mg dalbava ncin ) B  (1500 mg dalbava ncin ) C  (plac ebo) D (moxifloxacin)
ig. 3. Change from time-matched baseline QTcF (QTcF) (mean and 90% conﬁ-
ence interval) across treatment groups.12.9 ms  at 2 h, with the lower bound of the 90% CI exceeding 5 ms
at all three pre-speciﬁed time points (lower bound of 90% CI 10.5 ms
at 2 h, 7.1 ms  at 3 h and 8.6 ms  at 4 h) (Table 1).
There were no subjects with a QTcF value exceeding 480 ms
at any time point post dosing. Two subjects in the dalbavancin
1000 mg  had QTcF values exceeding 450 ms  at a total of six time
points, and no subjects in the dalbavancin 1500 mg had QTcF val-
ues above this threshold. Two subjects in the placebo group (at 8
time points) and four subjects in the moxiﬂoxacin group (at 13 time
points) had QTcF values exceeding 450 ms.  No subjects had a QTcF
exceeding 60 ms  at any of the time points. One subject in the dalba-
vancin 1000 mg  had a slightly negative T-wave at one time point,
but no other T-wave morphology changes were observed in the dal-
bavancin treatment groups. Notched, ﬂattened, diphasic or slightly
negative T-waves were occasionally observed in the placebo and
moxiﬂoxacin treatment groups.
The precision of the QTc measurements was  calculated as the
standard deviation of the QTcF. The mean standard deviation
for QTcF across time points and subjects was 6.2 ms on placebo,
7.6 ms  on moxiﬂoxacin, 6.6 ms  on dalbavancin 1000 mg  and 8.8 ms
on dalbavancin 1500 mg.
A concentration–effect model with a mean intercept ﬁxed to
zero with variability was found to ﬁt the data best. The relationship
between dalbavancin plasma levels and QTcF was very shallow
(Fig. 4A); a small, concentration-dependent effect of dalbavancin
on the placebo-corrected, change-from-baseline QTcF (QTcF)
was identiﬁed with an estimated slight negative population slope
of −0.0051 ms  per g/mL (90% CI−0.0078 to −0.0024) (Fig. 4B).
The predicted QTcF at the geometric mean peak dalbavancin
plasma concentration observed after 1000 mg  (285 g/mL; 90% CI
275 to 294) was  −1.5 ms  and after 1500 mg  (421 g/mL; 90% CI 408
to 434) was  −2.1 ms.The effect of dalbavancin on cardiac conduction (PR and QRS
intervals) was  small and there were no notable differences across
treatments groups. The placebo-corrected effect (PR) was
slightly reduced in the dalbavancin groups with a biggest change
M.W. Dunne et al. / International Journal of Antimicrobial Agents 45 (2015) 393–398 397
Fig. 4. (A) Scatter plot of observed QTcF–plasma concentration pairs from all subjects receiving dalbavancin. Data from the 1000 mg  dalbavancin group are shown
as  open circles and data from the 1500 mg group as grey squares. The mean population predicted QTc effect is shown as a solid red line. (B) Goodness-of-ﬁt plot
for  observed and predicted relation between dalbavancin plasma levels and QTcF. The solid black line and grey shaded area show the predicted mean effect
using  a linear model with an intercept with 90% conﬁdence interval (CI). The horizontal red lines with notches shows the range of dalbavancin plasma concentra-
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f −2.8 ms  (90% CI−5.5 to −0.1) at 3 h in the 1000 mg  group and of
3.6 ms  (90% CI−6.3 to −0.8) at 4 h in the 1500 mg  group. The reduc-
ion in the moxiﬂoxacin group was of the same magnitude [−3.8 ms
90% CI−5.9 to −1.7) at 3 h]. Treatment with dalbavancin had no
eaningful effect on the QRS interval. The mean placebo-corrected
hange from baseline QRS (QRS) were between −1.0 ms  and
.7 ms  at all time points post dosing of dalbavancin.
.3. Safety
One serious adverse event of ectopic pregnancy, unrelated to the
tudy drug, occurred in the dalbavancin 1000 mg  treatment group.
wo subjects discontinued study treatment: one subject adminis-
ered dalbavancin 1500 mg  exhibited red man  syndrome and one
ubject in the placebo group experienced infusion site extrava-
ation. One subject administered dalbavancin 1000 mg developed
symptomatic thrombocytopenia on Day 2; recovery started on
ay 3 and was complete by Day 26 without treatment.
. Discussion
Dalbavancin is indicated for the treatment of ABSSSI known
r suspected to be caused by Gram-positive pathogens. Based on
avourable pharmacokinetics with a long half-life, dalbavancin can
e given in a weekly dosing regimen, which has the potential
o decrease the burden of care associated with this disease by
liminating the need for an indwelling catheter. This simpliﬁed
reatment regimen will enable selected patients to be treated in
n outpatient setting. Patients with serious skin infections are typ-
cally >50 years of age and tend to have multiple co-morbidities,
ncluding diabetes, congestive heart failure and atherosclerotic
eart disease. For these patients, it is important for clinicians
o understand the impact of an antibiotic on ECG parameters.
nother lipoglycopeptide antibiotic, telavancin, has been found
o prolong the QTc interval and consequently it is important to
valuate whether this is a class effect or an effect speciﬁc to
elavancin.QTcF with 90% CI displayed at the median plasma concentration within each
Data from PK studies of dalbavancin demonstrate that the
pharmacokinetics are dose-proportional [12]. Based on data from
healthy volunteers, the projected mean Cmax after a single i.v. dose
of 1500 mg  over 30 min  is ca. 428 g/mL. Such plasma levels would
well exceed the maximum Cmax observed in the vast majority
of patients receiving the therapeutic dose of 1000 mg,  including
a signiﬁcant majority of those with impaired renal or hepatic
function. A population PK study using Monte Carlo simulation
demonstrated that patients with both renal impairment and
low body surface area, the most extreme outlying population,
would have a Cmax of ca. 430 g/mL, which is ca. 130% of the Cmax
of 287 g/mL seen in the normal population. Plasma levels in
‘worst-case scenario’ patients are therefore substantially below
the achieved mean Cmax level after the 1500 mg dose in this study,
thereby demonstrating that the ECG assessment in this study was
done at plasma levels well exceeding those in patients, as required
by the ICH E14 guidance [2,3]. Furthermore, given the lack of
QT signal in prior phase 1 studies or in ECG data from over 500
patients in phase 3 studies, it was deemed that if a QTc effect of
10 ms  could be excluded at plasma levels achieved by a dose of
1500 mg,  it can be concluded that dalbavancin would not cause
clinically relevant QTc prolongation in patients.
QT prolongation is quite commonly associated with anti-
infective drugs from various classes, e.g. ﬂuoroquinolones
(moxiﬂoxacin and levoﬂoxacin [13,14]), macrolides [15], azole anti-
fungals [16], antimalarials [16,17] and some drugs used for the
treatment of tuberculosis, e.g. bedaquiline [18]. Within the group of
anti-infectives indicated for ABSSSI [19], telavancin has been shown
to prolong the QTc interval [20,21] and is classiﬁed as a drug with
‘possible’ torsades de pointes risk (https://www.crediblemeds.org).
The thorough QT study with telavancin was  conducted before the
implementation of the ICH E14 guidance and the analysis was
therefore not performed in the same way as in the current study:
endpoints included the mean and maximum QTc effect within
each subject over 17 post-dosing time points [20]. Telavancin,
placebo and moxiﬂoxacin were administered to healthy volun-
teers in a parallel designed study with 160 subjects (n = 40 in each
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reatment group). The placebo-corrected maximum effect on QTcF
n Day 3 was 11.6 ms  (upper bound of 90% CI 16 ms)  after tela-
ancin 7.5 mg/kg and 15.1 ms  (upper bound of 90% CI 20 ms)  after
5 mg/kg. By extrapolation of data from these two  doses, a QTc
ffect of 12–15 ms  can be estimated at the end of a 10 mg/kg
nfusion [21]. In phase 3 trials, the incidence of QTc prolongation
f >60 ms  from baseline or QTcF > 500 ms  was 8% (52 patients)
n the telavancin group compared with 7% (48 patients) among
ancomycin-treated patients [21].
In contrast, no evidence of a clinically relevant effect of dal-
avancin on cardiac repolarisation was identiﬁed in this trial. The
argest mean placebo-corrected QTcF (QTcF) was  1.5 ms  at 6 h
fter dosing of dalbavancin 1000 mg  (90% CI−0.6 to 3.6) and only
.2 ms  (90% CI−1.7 to 2.0) at 24 h after 1500 mg,  with negative val-
es at all other post-dosing time points (Table 1). The study’s ‘assay
ensitivity’ was clearly conﬁrmed by the moxiﬂoxacin response
ith a largest QTcF of 12.9 ms  at 2 h, with the lower bound of
he 90% CI exceeding 5 ms  at all three pre-speciﬁed time points
Table 1). There were no subjects with a QTcF value exceeding
80 ms  and no subjects with a QTcF exceeding 60 ms  at any of
he post-dosing time points.
Exposure response analysis of QTc/plasma level data demon-
trated a very shallow relationship (Fig. 4A) with a small, negative
oncentration-dependent effect of dalbavancin on QTcF with
 population slope of −0.0051 ms  per g/mL (90% CI−0.0078
o −0.0024) (Fig. 4B). The QTcF effects using the linear
oncentration–effect model can be estimated to −1.5 ms  and
2.1 ms  after dosing with 1000 mg  and 1500 mg,  respectively,
hich is clearly without any clinical signiﬁcance. Similarly, the
ffects of dalbavancin on cardiac conduction (PR and QRS intervals)
ere small and without clinical relevance.
Based on these data, it can be concluded that dalbavancin does
ot affect cardiac repolarisation or conduction and will not cause
linically relevant QTc prolongation in patients.
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